| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age.
|
Vaccine
|
1998
|
1.14
|
|
2
|
Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants.
|
J Pediatr
|
1997
|
1.10
|
|
3
|
Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program.
|
Am J Public Health
|
1998
|
1.08
|
|
4
|
Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age.
|
Pediatr Infect Dis J
|
1994
|
1.07
|
|
5
|
An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.
|
Vaccine
|
2000
|
1.05
|
|
6
|
A swimming pool-associated outbreak of Cryptosporidiosis in British Columbia.
|
Can J Public Health
|
1994
|
0.89
|
|
7
|
Giardiasis outbreak from a chlorinated community water supply.
|
Can J Public Health
|
1991
|
0.88
|
|
8
|
Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.
|
Vaccine
|
2007
|
0.86
|
|
9
|
Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?
|
CMAJ
|
1993
|
0.83
|
|
10
|
Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children.
|
Vaccine
|
1995
|
0.83
|
|
11
|
An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
|
Vaccine
|
2006
|
0.83
|
|
12
|
Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection.
|
Vaccine
|
1992
|
0.81
|
|
13
|
Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia.
|
Can Dis Wkly Rep
|
1989
|
0.80
|
|
14
|
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
|
Pediatr Infect Dis J
|
1999
|
0.80
|
|
15
|
Breastfeeding and antibody responses to routine vaccination in infants.
|
Lancet
|
1992
|
0.79
|
|
16
|
Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life.
|
Vaccine
|
1996
|
0.79
|
|
17
|
Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
|
Scand J Infect Dis
|
1995
|
0.77
|
|
18
|
Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines.
|
J Pediatr
|
1999
|
0.76
|
|
19
|
Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine.
|
Vaccine
|
1997
|
0.76
|
|
20
|
Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants.
|
Can J Infect Dis
|
1994
|
0.75
|
|
21
|
A comparative study of PENTA vaccine booster doses given at 12, 15, or 18 months of age.
|
Vaccine
|
1999
|
0.75
|
|
22
|
Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age.
|
Hum Vaccin
|
2005
|
0.75
|
|
23
|
Is Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) compatible with diphtheria-pertussis-tetanus vaccine in young infants?
|
Pediatr Infect Dis J
|
1993
|
0.75
|
|
24
|
Measles outbreak in a Vancouver school population: relative risk and vaccine efficacy.
|
Can J Public Health
|
1988
|
0.75
|